Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
129 hedge funds and large institutions have $605M invested in Orexigen Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 57 increasing their positions, 32 reducing their positions, and 21 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 32
30% more capital invested
Capital invested by funds: $467M → $605M (+$138M)
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
20% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $10.2M
4% more funds holding
Funds holding: 124 → 129 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$11.5M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$11.3M |
| 5 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
+$8.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$22.5M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$13.1M |
| 3 |
AC
Apex Capital
Orinda,
California
|
-$5.63M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.59M |
| 5 |
First Manhattan
New York
|
-$5.08M |
OREX Hedge Fund Activity: Q1 2014 in Review
129 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q1 2014, worth a combined $605M — up 30% from $467M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new OREX positions and 21 closed out — a net gain of 6 holders — while 57 added to existing stakes and 32 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $25.9M. The largest seller was SAC Capital Advisors, cutting an estimated $22.5M.
- 129 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q1 2014, up from 124 in Q4 2013.
- Funds reported $605M of Orexigen Therapeutics, Inc. stock for Q1 2014, up 30% quarter-over-quarter.
- 27 funds opened new Orexigen Therapeutics, Inc. positions in Q1 2014 and 21 closed out, a net change of +6 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $25.9M added.
- The largest Orexigen Therapeutics, Inc. seller in Q1 2014 was SAC Capital Advisors, an estimated $22.5M sold.
Based on aggregated 13F filings for Q1 2014.